Immunovant (IMVT) Change in Cash (2019 - 2026)

Immunovant (IMVT) has 8 years of Change in Cash data on file, last reported at -$92.4 million in Q1 2026.

• Quarterly Change in Cash fell 127.24% year-over-year to -$92.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $188.1 million (up 139.34% YoY) and the FY2026 annual result came in at $188.1 million, up 139.34% from the prior year.
• Change in Cash slipped to -$92.4 million in Q1 2026, from $472.7 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $472.7 million in Q4 2025 to a low of -$115.1 million in Q2 2025.
• A 5-year average of $22.1 million and a median of -$56.1 million in 2023 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2022 — Change in Cash plunged 215.08% — and 2023, when it jumped 1468.88%.
• Tracing IMVT's Change in Cash over 5 years: stood at $26.8 million in 2022, then jumped by 1468.88% to $421.0 million in 2023, then slumped by 123.34% to -$98.3 million in 2024, then jumped by 581.04% to $472.7 million in 2025, then sank by 119.55% to -$92.4 million in 2026.
• The last three Change in Cash figures came in at -$92.4 million (Q1 2026), $472.7 million (Q4 2025), and -$77.0 million (Q3 2025), per Business Quant data.